Medistep Healthcare IPO Details
The key details of Medistep Healthcare’s IPO are outlined below, covering all crucial aspects from price range to investment requirements and regulatory documents.
| IPO Size | ₹16.10 Cr |
| Price Range | ₹43 |
| Retail Quota | 50% |
| QIB Quota | -- |
| NII Quota | 50% |
| Employee Discount | -- |
| Listing at | NSE |
| Minimum Quantity | 6,000 |
| Investment (cut-off price) | ₹2,58,000 |
| Pre IPO Promotor Holding | 93.62% |
| Post IPO Promotor Holding | 68.96% |
| DHRP Draft | Click Here |
| RHP Draft | Click Here |
| Anchor Investors List | Click Here |
Medistep Healthcare IPO Timelines
The IPO process for Medistep Healthcare includes key dates for participants to know. The timeline allows for strategic planning and participation, helping investors stay informed and engaged throughout the entire process.
08/08/2025
Start Date12/08/2025
End Date14/08/2025
Refund Initiation14/08/2025
Credit of Shares to Demat Ac18/08/2025
Listing DateMedistep Healthcare IPO Lot Size
The Medistep Healthcare IPO has a fixed lot size of 3,000 shares, at a price of ₹43 per share. For retail investors, the minimum and maximum application is 6,000 shares (2 lots) amounting to ₹2,58,000. For HNI investors, the minimum application is 9,000 shares (3 lots), which totals ₹3,87,000.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 2 | 6000 | ₹2,58,000 |
| Retail Maximum | 2 | 6000 | ₹2,58,000 |
| HNI Minimum | 3 | 9000 | ₹3,87,000 |
Medistep Healthcare IPO Subscription Status
The subscription status for Medistep Healthcare IPO shows market demand across different investor categories, providing valuable insights into the offering’s performance. You can track real-time subscription data below.
| QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|
| -- | 289.15x | 461.11x | -- | 382.14x |
IPO Performance on Listing Day
On the listing day (August 18, 2025), Medistep Healthcare made an impressive debut on the stock exchange. The stock opened at ₹53, commanding a strong premium of 23.3% over its issue price of ₹43. The healthcare company maintained this opening level as its day high, demonstrating initial investor enthusiasm. However, profit-booking emerged during the session, with the stock retreating to ₹50.35, which also became the day’s low. The shares concluded their maiden trading day at ₹50.35, still delivering a robust gain of 17.1% over the issue price, reflecting strong market confidence in this healthcare services provider despite some intraday volatility.
| Opening Price | Closing Price | Day High | Day Low |
|---|---|---|---|
| ₹53.00 | ₹50.35 | ₹53.00 | ₹50.35 |
Medistep Healthcare IPO Company Financials
Medistep Healthcare reports robust performance in FY2024 with Total Income of ₹31.63 crores, managing expenses at ₹27.66 crores, and achieving a strong PAT (Profit After Tax) of ₹2.91 crores, demonstrating significant growth potential ahead of its public offering.
| Year | Total Income | Total Expense | PAT |
|---|---|---|---|
| FY 2022 | ₹7.62 | ₹7.27 | ₹0.19 |
| FY 2023 | ₹27.74 | ₹26.31 | ₹0.92 |
| FY 2024 | ₹31.63 | ₹27.66 | ₹2.91 |
| FY 2025 (3 M) | ₹11.25 | ₹9.86 | ₹1.02 |
About Company
Incorporated in June 2023, Medistep Healthcare Limited is a public, non-government pharmaceutical company dedicated to producing a wide range of health and wellness products. Their offerings include high-quality sanitary pads, energy powders, pharmaceutical and nutraceutical products, as well as intimate care and surgical items. The company emphasizes quality in its manufacturing and trading operations, aiming to expand its diverse product line to meet growing healthcare demands.
As of December 30, 2024, Medistep reported annualized revenues of ₹45.00 crore with a Profit After Tax (PAT) of ₹4.08 crore. The company operates with a lean team of nine payroll employees, relying primarily on daily-paid labor for production needs. With a focus on accessible and essential health products, Medistep continues to support public health while planning for sustainable growth in the healthcare sector.
| Incorporation Date | Sector | Managing Director |
|---|---|---|
| 2023 | Healthcare | Girdhari Lal Prajapati |
Know Before Investing
Medistep Healthcare IPO Strengths
- The company’s manufacturing of sanitary pads and wellness products addresses critical needs in women’s hygiene and preventive care, tapping a high-growth and socially impactful niche.
- Though incorporated recently, Medistep has posted significant revenue growth, expanding from ₹7.62 crore in FY22 to ₹31.63 crore by FY24, reflecting strong market demand and business agility.
- Led by industry veterans such as Mr. Girdharilal Prajapat (MD) and supported by experienced professionals with 10-20+ years in pharmaceuticals, hospital management, sales, and strategy, bolstering operational expertise and credibility.
- The company emphasizes rigorous quality standards, continuous improvement, and a customer-centric approach, driving recurring business and building long-term relationships.
- Medistep is geared towards timely development of new products, resource optimization, and adapting to diverse geographies, helping it to stay ahead in a fast-evolving healthcare sector.
- With a small team and flexible business systems, the company can quickly respond to market needs, new opportunities, and changes in the regulatory environment.
Medistep Healthcare IPO Risks
- Medistep Healthcare operates in the healthcare and personal care sector, which is highly competitive with numerous established players, potentially limiting market share growth and putting pressure on pricing.
- The company relies on timely procurement of raw materials for manufacturing sanitary pads, energy powder and other healthcare products. Supply chain disruptions or price volatility could adversely affect production and costs.
- Inventory management, receivables collection, and supplier payments require strong working capital management. Inefficiencies could strain liquidity and cash flows.
- Being in the personal care and healthcare products segment, stringent regulatory requirements apply regarding product safety, labeling, and marketing. Non-compliance could lead to penalties or market restrictions.
- New product launches or existing product categories are subject to changing consumer tastes and market acceptance. Failure to innovate or respond to market trends can reduce sales potential.
- Keeping skilled workforce and management is critical to maintain operational efficiency and growth plans. Talent shortages or attrition can disrupt business.
Swot Analysis for Medistep Healthcare IPO
Strengths
Commitment to Quality and Ethics, Flexible Trading and Manufacturing Structure, Expansion Across Geographies
Weaknesses
Limited Operating Track Record, Unproven Large-Scale Manufacturing Capacity, Brand Recognition Still Emerging
Opportunities
Growth in Affordable Healthcare, New Product Launches and Diversification, B2B and Government Partnerships
Threats
Intense Pharma and FMCG Competition, Stringent Regulatory Environment, Economic and Policy Fluctuations
Company Details
Medistep Healthcare Ltd.
05, S. No-245/B, Plot-19, T.P.S. 56, Free Way Trade Center, Nr.A-One Hotel, N.H.-8, Narol Gam, Narol ,Ahmadabad City, Daskroi, Gujarat, India, 382405
Phone: +91 87808 46963
Email: Info@medistephc.com
Website: https://www.medistephc.com/
IPO Registar Details
Cameo Corporate Services Limited
Phone: +91-44-28460390
Email: ipo@cameoindia.com
Website: https://ipo.cameoindia.com/
FAQs
The key objectives of Medistep Healthcare IPO are:
- Funding of capital expenditure towards purchase of plant and machineries for expansion at the existing manufacturing facility
- Working Capital requirements
- General Corporate Purpose
Fast Track Finsec Pvt Ltd is the book-running lead managers for the Medistep Healthcare IPO.
Medistep Healthcare has shown early profitability with ₹31.63 crore in revenue and ₹2.91 crore profit in FY24, supported by a total asset base of ₹14.96 crore. While the company is still modest in scale, its positive margins suggest potential for steady growth if operational efficiency and market reach improve.
The issue price for the Medistep Healthcare IPO is set to ₹43 per share.
To invest in two lot of Medistep Healthcare IPO, you need ₹2,58,000 at the fixed price band (₹43 per share) for a lot size of 6,000 shares.
Medistep Healthcare IPO shares are scheduled to be listed on the National Stock Exchange (NSE) on August 18, 2025.
Refund/unblocking of funds for Medistep Healthcare IPO will begin on August 14, 2025. ASBA/UPI blocks will be removed within 1 working day.
You can sell shares your Medistep Healthcare IPO shares on listing day (August 18, 2025) after they are credited to your demat account. If you want to sell in the pre-open market, the timing for that session is from 9:00 AM to 9:15 AM. Otherwise, you can sell after 10:00 AM during regular trading hours.